Pharmaceuticals

Sanofi

Sanofi Requests Withdrawal of Diabetes Drug from FDA Priority Review Vouchers Program

Sanofi Issued 1 Billion Euro 3% Bond

Sanofi issued 650 million euros of medium-term notes

Sanofi Invests $294 Million in Expanding Toronto AI Center of Excellence

Sanofi prices 2.3 billion euros bond issuance

Sanofi Announces Lower Side Effects in Nuvaxovid Phase 4 Data Compared to Moderna

Sanofi Prices €2.3 Billion Bond Offering

Sanofi Reports Q1 Sales Above Expectations and Reaffirms High-Single-Digit Growth Guidance for 2026

Swiss bank analyst maintains hold rating on Sanofi

Sanofi's Multiple Sclerosis Drug Cenrifki Receives Positive CHMP Recommendation

Sanofi released FY2026 Q1 earnings on April 23 (EST), actual revenue USD 12.89 B (forecast USD 11.72 B), actual EPS USD 1.5359

Sanofi released FY2026 Q4 earnings on April 23 (EST), actual revenue USD 12.89 B (forecast USD 14.13 B), actual EPS USD 1.5359

Sanofi Reports Q1 Operating Net Income Rise, Dupixent Sales Soar

Sanofi Exceeds Earnings Per Share Expectations in Q1

FDA Approves Tzield for Children Aged 1 and Older to Delay Progression from Type 2 to Type 3 Diabetes

Sanofi to Release FY2026 Q1 Earnings on April 22 (EST), Forecast Revenue USD 11.95 B

Sanofi Receives EU Conditional Market Approval for GvHD Drug

Sanofi Announces Positive Phase III Results of Amlitelimab for Moderate to Severe Atopic Dermatitis

Sanofi's Sarclisa Subcutaneous Formulation Recommended for Approval by the EU

Sanofi Receives FDA Breakthrough Therapy Designation for Treating Type 3 Gaucher Disease

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SNYNF

SBIO

IBBQ

75 senior leaders from the pharmaceutical industry announced a new operating model for pharma marketing at the Doceree Makers Summit. They declared the end of the fragmented software stack that has dominated the industry for two decades and introduced Daily Command, a unified system designed to streamline workflows for brand teams. This coordinated effort, involving major companies like Sanofi and Merck, aims to replace the existing tools with a single product that enhances efficiency and decision-making in pharma marketing. Daily Command will officially launch on May 7, 2026, with a closed beta starting in June.

prnewswire

Merck

VanEck Biotech ETF

Ark Genomic Revolution ETF

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares US Pharma

17:15 ET75 of Pharma's Most Senior Marketers Just Walked Away From a $12 Billion Tool Stack

Sanofi has become an inaugural sponsor of AlphaDetect, a nonprofit organization focused on accelerating the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1). This partnership aims to enhance awareness and testing for this underdiagnosed genetic condition, which significantly impacts lung and liver health. Sanofi's support will help expand detection strategies and improve patient outcomes by ensuring earlier diagnosis. Alpha-1 remains largely undiagnosed, with over 90% of affected individuals unidentified. The collaboration reflects Sanofi's commitment to the Alpha-1 community and rare disease initiatives.

StockTitan

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 | SNY Stock News

LABU

Sanofi plans to invest 294 million Canadian dollars ($216 million) to expand its AI Centre of Excellence in Toronto, aiming to enhance medicine development and delivery. The expansion will create 50 jobs focused on advanced AI tools and is supported by a conditional grant of up to CA$5 million from the Invest Ontario Fund. However, Sanofi's shares fell by 6% during Monday trading, closing at $43.30.

Fidelity

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

Sanofi Plans $216 Million AI Center Expansion in Toronto

Merck KGaA has appointed Kai Beckmann as its new CEO, succeeding Belén Garijo, who has moved to Sanofi. Garijo completed her tenure at Merck KGaA after 15 years, including two years as CEO. Beckmann, who has been with the company since 1989 and served on the Executive Board since 2011, was appointed in September 2022. Garijo's transition to Sanofi is expected to enhance the company's strategic implementation.

rttnews

Merck KGaA

Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO

Sanofi shareholders approved Belén Garijo's appointment as CEO during the annual general meeting on April 29, effective May 1. This leadership change coincides with the approval of the 2025 accounts and a dividend of $4.81 per share, indicating a governance reset at the biopharmaceutical company. Garijo, with a strong background in R&D and operational leadership, aims to enhance execution discipline and capital allocation. The board also renewed mandates for existing members and appointed new independent board members, reflecting a commitment to diversity and governance improvements.

Pharmexec

ORANGE SPON ADR EACH REPR 1 ORD SHS

<![CDATA[Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote]]>

The European Medicines Agency (EMA) has established a new advisory group to enhance vaccine confidence amid rising hesitancy in Europe. This group, comprising healthcare professionals, academics, and public health representatives, will meet quarterly as part of the EMA's Vaccine Outreach Strategy. Recent WHO data indicates that childhood vaccination rates remain below pre-pandemic levels, increasing vulnerability to diseases. EMA's Executive Director emphasized the importance of transparent communication to rebuild public trust in vaccines. Sanofi supports this initiative, highlighting the need for coordinated action across European Member States to combat vaccine hesitancy.

Fiercepharma

EMA establishes new group to counter vaccine hesitancy

Sanofi (EPA:SAN) is set to trade ex-dividend soon, with a dividend of €4.12 per share. However, the company has paid out 102% of its earnings in dividends, raising concerns about sustainability. While it generated enough free cash flow to cover 70% of its dividend, its earnings per share have declined by 16% annually over the past five years. This trend suggests that the dividend may not grow quickly in the future, leading analysts to advise caution for potential investors.

Simplywall

Why It Might Not Make Sense To Buy Sanofi (EPA:SAN) For Its Upcoming Dividend

Sanofi(SNYNF.US)